Table 1.

Selected ongoing studies utilizing ICB

NCI identifierTrial titlePhaseStatusPatient cohort
NCT01592370An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients with Multiple MyelomaIOpenRelapsed
NCT02431208A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or inCombination with an Immunomodulatory Drug and/or Daratumumab in Participantswith Multiple Myeloma (MM)IbOpenRelapsed
NCT03267888Pembrolizumab and Radiation Therapy in Patients with Relapsed or Refractory MultipleMyelomaIOpenRelapsed
NCT03168438NY-ESO-1c259T Alone and in Combination with Pembrolizumab for Multiple MyelomaIIOpenRelapsed
NCT03292263ASCT with Nivolumab in Patients with Multiple MyelomaI/IIOpenNewly diagnosed or relapsed
NCT03605719Dexamethasone, Carfilzomib, and Nivolumab with Reovirus for Relapsed/RefractoryMultiple MyelomaIOpenRelapsed
NCT03184194Nivolumab Combined with Daratumumab with or without Low-Dose CyclophosphamideIIOpenRelapsed
NCT03634800Radiotherapy with Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M)IIOpenRelapsed
NCT02681302Check Point Inhibition after Autologous Stem Cell Transplantation in Patients at High Riskof Posttransplant Recurrence (CPIT001)I/IIOpenRelapsed
NCT03312530A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or without Atezolizumab, in Participants with Relapsed and Refractory MultipleMyelomaI/IIOpenRelapsed
NCT03111992Study of Single-Agent CJM112, and PDR001 in Combination with LCL161 or CJM112 in Patients with Multiple MyelomaIOpenRelapsed
NCT03194867Isatuximab in Combination with Cemiplimab in Relapsed/Refractory Multiple Myeloma(RRMM) PatientsI/IIOpenRelapsed
NCT03782064Dendritic Cell (DC)/Myeloma Fusions in Combination with Nivolumab in Patients withRelapsed Multiple MyelomaIIOpenRelapsed